Press release
Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:\n\n\nCiti’s 15th Annual BioPharma Virtual Conference\n\n\nSeptember 9, 2020 – Arrowhead management will participate in investor meetings\n\n\nBaird's 2020 Global Healthcare Conference\n\n\nSeptember 10, 2020, 2:00 p.m. EDT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation\n\n\nH.C. Wainwright 22nd Annual Global Investment Conference\n\n\nSeptember 15, 2020, 9:30 a.m. EDT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation\n\n\nCantor Fitzgerald Global Healthcare Conference 2020\n\n\nSeptember 15, 2020, 2:00 p.m. EDT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation\n\n\nA copy of the presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.\n\n\nAbout Arrowhead Pharmaceuticals\n\n\nArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.\n\n\nFor more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.\n\n\nSafe Harbor Statement under the Private Securities Litigation Reform Act:\n\n\nThis news release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of vario...